All In Biotech

Drug Trial Radar · NCT07839819

Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies

Phase 1/2 Master Study to Assess the Safety and Efficacy of PM54 in Combination With Cytotoxic and Targeted Agents for the Treatment of Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

231

Planned (sponsor's estimate)

Start

Nov 12, 2026

Primary completion

Sep 27, 2029

Study completion Nov 27, 2029

Sponsor

Lead sponsor
PharmaMarIndustry
Sponsor type
Industry
First posted
Sep 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the safety, tolerability and recommended dose (RD) of PM54 in combination with cytotoxic and targeted anticancer agents in adult participants with advanced solid tumors. The study will also assess the antitumor activity of PM54 in combination with cytotoxic and targeted anticancer agents in terms of objective response rate (ORR) based on investigator's assessment in participants in other cohorts.

Conditions

  • Advanced Solid Tumor

Interventions

  • PM54Drug

    Intravenous infusion.

  • IrinotecanDrug

    Intravenous infusion.

  • DoxorubicinDrug

    Intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1 and 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Treatment Discontinuation or Dose ModificationsTime frame: Time from the first administration of study intervention until 30 days after study intervention discontinuation or initiation of new subsequent anticancer therapy, whichever occurs first (up to 5 years)
  2. Part 1: Number of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Cycle 1 (each cycle is of 21 days)
  3. Part 2: Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1Time frame: Baseline up to 5 years

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Institut Bergonie

    Bordeaux, France

  • Centre Leon Berard - Lyon

    Lyon, France

  • Centre Antoine Lacassagne

    Nice, France

  • Helios Klinikum Berlin-Buch

    Buckow, Germany

  • Universitaetsmedizin Mainz

    Mainz, Germany

  • START Lisbon - ULS Santa Maria

    Lisbon, Portugal

  • Instituto Portugues De Oncologia Do Porto Francisco Gentil Epe Ipo Porto Ipopfg Clinica De Onco Hematologia

    Porto, Portugal

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.